Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 16/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 16/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 15/20 | 1.00 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.84 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20523451 | 0.95 | NOD2 (0.91) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL21630430 | 0.92 | ACVR1 (1.00) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL21630435 | 0.92 | NOD2 (1.00) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL20523499 | 0.91 | NOD2 (1.00) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL20523667 | 0.91 | NOD2 (1.00) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL20523577 | 0.91 | NOD2 (0.84) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL20523447 | 0.91 | NOD2 (1.00) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL20523618 | 0.85 | NOD2 (0.84) | NOD2ACVR1RIPK2NOD1 | |
| SCHEMBL21630444 | 0.85 | NOD2 (1.00) | NOD2ACVR1RIPK2NOD1TGFBR1 | |
| SCHEMBL31285446 | 0.84 | NOD2 (0.73) | NOD2ACVR1RIPK2NOD1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136386-B2 | Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210277477-A1 | METHODS OF TREATING REFRACTORY INFLAMMATORY DISEASE USING TRANSCRIPTOMIC AND GENETIC RISK SIGNATURES | CEDARS-SINAI MEDICAL CENTER | 2021-09-09 | — | — | US | disclosed |
| EP-3600307-B1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIV HOUSTON SYSTEM (US) | 2021-05-05 | — | — | EP | disclosed |
| US-20210101988-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | CEDARS-SINAI MEDICAL CENTER | 2021-04-08 | — | — | US | disclosed |
| US-20210079473-A1 | METHODS AND SYSTEMS FOR CHARACTERIZING SEVERE CROHN'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| WO-2020232125-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200362025-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | CEDARS-SINAI MEDICAL CENTER | 2020-11-19 | — | — | US | disclosed |
| WO-2020139748-A1 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2 | CEDARS-SINAI MEDICAL CENTER (US) | 2020-07-02 | — | — | WO | disclosed |
| EP-3600307-A1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | University of Houston System (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2018183633-A1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200362025-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | NOD2 4679/4885ACVR1 1819/4885RIPK2 4403/4885 |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | NOD2 4679/4885ACVR1 1819/4885RIPK2 4403/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | NOD2 4679/4885ACVR1 1819/4885RIPK2 4403/4885 |
| US-20210101988-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | NOD2 4679/4885ACVR1 1819/4885RIPK2 4403/4885 |
| US-11136386-B2 | Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) | LTA, TLL1, TNF | NOD2 568/4885ACVR1 551/4885RIPK2 2417/4885 |
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | RIPK2, RIPK1, NOD2 | NOD2 3/4885ACVR1 8/4885RIPK2 1/4885 |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | RIPK2, RIPK1, NOD2 | NOD2 3/4885ACVR1 8/4885RIPK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.